Lp(a) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank

This analysis of 460,506 UK Biobank participants — the largest single study of Lp(a) and cardiovascular outcomes to date — quantified the Lp(a)-ASCVD risk relationship across the full Lp(a) distribution, examined racial variation in both Lp(a) levels and associated risk, and evaluated the clinical relevance of the ≥150 nmol/L threshold being used to enroll patients in Lp(a)-lowering trials.

The relationship between Lp(a) and incident ASCVD (CAD and ischemic stroke) was continuous and linear, with no evidence of a threshold below which Lp(a) conferred no excess risk. Each 50 nmol/L increment in Lp(a) was associated with an 11% higher ASCVD hazard across the distribution. Striking racial differences in median Lp(a) were observed: Black individuals had a median of 75 nmol/L versus 19 nmol/L for White individuals — reflecting the well-known genetic basis of Lp(a) elevation and its higher prevalence in African ancestry populations. Despite these concentration differences, the risk per 50 nmol/L increment was similar across racial groups.

The ≥150 nmol/L threshold used in the Lp(a)HORIZON outcomes trial appropriately identified a high-risk enriched population — but captured substantially more Black and South Asian individuals than White individuals given the distributional differences, raising equity considerations for how trial results will generalize.

For clinical practice, this analysis reinforces that Lp(a) risk is continuous, not categorical. Patients with Lp(a) of 80 nmol/L carry meaningful risk even if below the clinical action threshold — and the racial distribution of Lp(a) argues for universal measurement rather than selective testing.

We rate the evidence strong. A definitive large-scale biobank analysis characterizing the Lp(a)-ASCVD risk gradient and its variation across racial groups — foundational context for emerging Lp(a)-specific therapies.